Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial
- PMID: 11710890
- DOI: 10.1001/jama.286.18.2251
Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial
Abstract
Context: Among cancer-free women aged 35 years or older, tamoxifen reduced the incidence of estrogen receptor (ER)-positive but not ER-negative breast cancer. The effect of tamoxifen on breast cancer incidence among women at extremely high risk due to inherited BRCA1 or BRCA2 mutations is unknown.
Objective: To evaluate the effect of tamoxifen on incidence of breast cancer among cancer-free women with inherited BRCA1 or BRCA2 mutations.
Design, setting, and participants: Genomic analysis of BRCA1 and BRCA2 for 288 women who developed breast cancer after entry into the randomized, double-blind Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project (between April 1, 1992, and September 30, 1999).
Main outcome measure: Among women with BRCA1 or BRCA2 mutations, incidence of breast cancer among those who were receiving tamoxifen vs incidence of breast cancer among those receiving placebo.
Results: Of the 288 breast cancer cases, 19 (6.6%) inherited disease-predisposing BRCA1 or BRCA2 mutations. Of 8 patients with BRCA1 mutations, 5 received tamoxifen and 3 received placebo (risk ratio, 1.67; 95% confidence interval, 0.32-10.70). Of 11 patients with BRCA2 mutations, 3 received tamoxifen and 8 received placebo (risk ratio, 0.38; 95% confidence interval, 0.06-1.56). From 10 studies, including this one, 83% of BRCA1 breast tumors were ER-negative, whereas 76% of BRCA2 breast tumors were ER-positive.
Conclusion: Tamoxifen reduced breast cancer incidence among healthy BRCA2 carriers by 62%, similar to the reduction in incidence of ER-positive breast cancer among all women in the Breast Cancer Prevention Trial. In contrast, tamoxifen use beginning at age 35 years or older did not reduce breast cancer incidence among healthy women with inherited BRCA1 mutations. Whether tamoxifen use at a younger age would reduce breast cancer incidence among healthy women with BRCA1 mutations remains unknown.
Similar articles
-
Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.J Clin Oncol. 2003 Dec 1;21(23):4322-8. doi: 10.1200/JCO.2003.02.107. J Clin Oncol. 2003. PMID: 14645421
-
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.Br J Cancer. 2002 Jan 21;86(2):218-21. doi: 10.1038/sj.bjc.6600064. Br J Cancer. 2002. PMID: 11870509 Free PMC article.
-
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.Int J Cancer. 2006 May 1;118(9):2281-4. doi: 10.1002/ijc.21536. Int J Cancer. 2006. PMID: 16331614
-
Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama.Ann Oncol. 2004;15 Suppl 1:I27-I34. doi: 10.1093/annonc/mdh654. Ann Oncol. 2004. PMID: 15280184 Review.
-
Chemoprevention for high-risk women: tamoxifen and beyond.Breast J. 2001 Sep-Oct;7(5):311-20. doi: 10.1046/j.1524-4741.2001.21570.x. Breast J. 2001. PMID: 11906441 Review.
Cited by 151 articles
-
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines.J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954. eCollection 2020. J Oncol. 2020. PMID: 32655641 Free PMC article. Review.
-
Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381. JCO Glob Oncol. 2020. PMID: 32628584 Free PMC article.
-
HRness in Breast and Ovarian Cancers.Int J Mol Sci. 2020 May 28;21(11):3850. doi: 10.3390/ijms21113850. Int J Mol Sci. 2020. PMID: 32481735 Free PMC article. Review.
-
Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.JCO Glob Oncol. 2020 Mar;6:439-452. doi: 10.1200/JGO.19.00170. JCO Glob Oncol. 2020. PMID: 32155091 Free PMC article.
-
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).Clin Transl Oncol. 2020 Feb;22(2):193-200. doi: 10.1007/s12094-019-02262-0. Epub 2019 Dec 30. Clin Transl Oncol. 2020. PMID: 31889241
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Research Materials
-
Miscellaneous